Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population
<h3>Purpose</h3><p dir="ltr">To identify the impact of <i>CYP2C9*2, *3, VKORC1−1639 G>A </i>and <i>CYP4F2*3</i> on warfarin dose in an Arab population. To compare the accuracy of a clinical warfarin dosing (CWD) versus genetic warfarin dosing al...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513540434427904 |
|---|---|
| author | Amr M. Fahmi (21632909) |
| author2 | Ahmed El Bardissy (22155949) Mohamed Omar Saad (12535545) Amr Fares (22155952) Ahmed Sadek (4588474) Mohamed Nabil Elshafei (9960500) Asma Eltahir (14158923) Asmaa Mohamed (19870274) Hazem Elewa (3592601) |
| author2_role | author author author author author author author author |
| author_facet | Amr M. Fahmi (21632909) Ahmed El Bardissy (22155949) Mohamed Omar Saad (12535545) Amr Fares (22155952) Ahmed Sadek (4588474) Mohamed Nabil Elshafei (9960500) Asma Eltahir (14158923) Asmaa Mohamed (19870274) Hazem Elewa (3592601) |
| author_role | author |
| dc.creator.none.fl_str_mv | Amr M. Fahmi (21632909) Ahmed El Bardissy (22155949) Mohamed Omar Saad (12535545) Amr Fares (22155952) Ahmed Sadek (4588474) Mohamed Nabil Elshafei (9960500) Asma Eltahir (14158923) Asmaa Mohamed (19870274) Hazem Elewa (3592601) |
| dc.date.none.fl_str_mv | 2024-09-25T15:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2024.102865 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Accuracy_of_an_internationally_validated_genetic-guided_warfarin_dosing_algorithm_compared_to_a_clinical_algorithm_in_an_Arab_population/30024427 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Genetics Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Warfarin/administration and dosage Clinical warfarin dosing Genetic guided warfarin dosing VKORC1 CYP2C9 CYP4F2 |
| dc.title.none.fl_str_mv | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Purpose</h3><p dir="ltr">To identify the impact of <i>CYP2C9*2, *3, VKORC1−1639 G>A </i>and <i>CYP4F2*3</i> on warfarin dose in an Arab population. To compare the accuracy of a clinical warfarin dosing (CWD) versus genetic warfarin dosing algorithms (GWD) during warfarin initiation. </p><h3>Methods</h3><p dir="ltr">A cohort of Arab patients newly starting on warfarin had their dose calculated using CWD published in www.warfarindosing.org and were followed for 1 month. Each patient provided a saliva sample. DNA was extracted, purified and genotyped for <i>VKORC−1639 G>A, CYP2C9*2, CYP2C9*3 </i>and<i> CYP4F2*3</i>. After reaching warfarin maintenance dose, the dose was recalculated using the GWD and median absolute error (MAE) and the percentage of warfarin doses within 20% of the actual dose were calculated and compared for the two algorithms. </p><h3>Results</h3><p dir="ltr">The study enrolled 130 patients from 12 Arabian countries. Compared to those with wild type, carriers of reduced function alleles in <i>CYP2C9</i> required significantly lower median (IQR) warfarin weekly dose [24.5 (15.3) vs. 35 (29.8) mg/week, p=0.006]. With regards to VKORC, patients with AA genotype had a significantly lower median (IQR) weekly warfarin dose compared to AG and GG [21(10.5) vs 29.4 (21), p<0.001 for AA vs AG, p<0.001 for AA vs GG]. The MAE (IQR) for the weekly dose of the GWD was significantly lower compared to CWD [8.1 (10.5) vs 12.4 (12.6) (p<0.001)]. </p><h3>Conclusion</h3><p dir="ltr"><i>CYP2C9 </i>and<i> VKORC1</i> variants are important determinants of warfarin dose in the Arab population. The use of the genetic and clinical factors led to better warfarin dose estimation when compared to clinical factors alone.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102865" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102865</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a85a1de1f33717d1db12d31c3151d1a7 |
| identifier_str_mv | 10.1016/j.cpcardiol.2024.102865 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30024427 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab populationAmr M. Fahmi (21632909)Ahmed El Bardissy (22155949)Mohamed Omar Saad (12535545)Amr Fares (22155952)Ahmed Sadek (4588474)Mohamed Nabil Elshafei (9960500)Asma Eltahir (14158923)Asmaa Mohamed (19870274)Hazem Elewa (3592601)Biological sciencesGeneticsBiomedical and clinical sciencesPharmacology and pharmaceutical sciencesWarfarin/administration and dosageClinical warfarin dosingGenetic guided warfarin dosingVKORC1CYP2C9CYP4F2<h3>Purpose</h3><p dir="ltr">To identify the impact of <i>CYP2C9*2, *3, VKORC1−1639 G>A </i>and <i>CYP4F2*3</i> on warfarin dose in an Arab population. To compare the accuracy of a clinical warfarin dosing (CWD) versus genetic warfarin dosing algorithms (GWD) during warfarin initiation. </p><h3>Methods</h3><p dir="ltr">A cohort of Arab patients newly starting on warfarin had their dose calculated using CWD published in www.warfarindosing.org and were followed for 1 month. Each patient provided a saliva sample. DNA was extracted, purified and genotyped for <i>VKORC−1639 G>A, CYP2C9*2, CYP2C9*3 </i>and<i> CYP4F2*3</i>. After reaching warfarin maintenance dose, the dose was recalculated using the GWD and median absolute error (MAE) and the percentage of warfarin doses within 20% of the actual dose were calculated and compared for the two algorithms. </p><h3>Results</h3><p dir="ltr">The study enrolled 130 patients from 12 Arabian countries. Compared to those with wild type, carriers of reduced function alleles in <i>CYP2C9</i> required significantly lower median (IQR) warfarin weekly dose [24.5 (15.3) vs. 35 (29.8) mg/week, p=0.006]. With regards to VKORC, patients with AA genotype had a significantly lower median (IQR) weekly warfarin dose compared to AG and GG [21(10.5) vs 29.4 (21), p<0.001 for AA vs AG, p<0.001 for AA vs GG]. The MAE (IQR) for the weekly dose of the GWD was significantly lower compared to CWD [8.1 (10.5) vs 12.4 (12.6) (p<0.001)]. </p><h3>Conclusion</h3><p dir="ltr"><i>CYP2C9 </i>and<i> VKORC1</i> variants are important determinants of warfarin dose in the Arab population. The use of the genetic and clinical factors led to better warfarin dose estimation when compared to clinical factors alone.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102865" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102865</a></p>2024-09-25T15:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2024.102865https://figshare.com/articles/journal_contribution/Accuracy_of_an_internationally_validated_genetic-guided_warfarin_dosing_algorithm_compared_to_a_clinical_algorithm_in_an_Arab_population/30024427CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/300244272024-09-25T15:00:00Z |
| spellingShingle | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population Amr M. Fahmi (21632909) Biological sciences Genetics Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Warfarin/administration and dosage Clinical warfarin dosing Genetic guided warfarin dosing VKORC1 CYP2C9 CYP4F2 |
| status_str | publishedVersion |
| title | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| title_full | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| title_fullStr | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| title_full_unstemmed | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| title_short | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| title_sort | Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population |
| topic | Biological sciences Genetics Biomedical and clinical sciences Pharmacology and pharmaceutical sciences Warfarin/administration and dosage Clinical warfarin dosing Genetic guided warfarin dosing VKORC1 CYP2C9 CYP4F2 |